Portable point-of-care blood tests, done by EMS before hospital arrival, need validation but could guide treatment and ...

Q32 Bio has stopped a Phase II trial of its former lead renal disease candidate as it focuses on its alopecia areata ...

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...

Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions ...

As we begin 2025, I wanted to take the opportunity to recap on the progress we made in 2024 and key upcoming catalysts including our planned entrance into the multi-billion dollar U.S. market. 2024 ...

Low-fiber fruits and vegetables, lean proteins, and foods rich in omega-3 fatty acids tend to be easier on an inflamed gut, ...

Gross profit expected to surge by 32.6%Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, ...

Qlaris Bio has reported positive topline outcomes from two Phase II US trials of QLS 111 in individuals with POAG and OHT.

Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 76 figures, this 149-page report Asia Pacific Single Cell Multiomics Market 2021-2031 by Product Type ...

The global single cell multiomics market is set to experience a remarkable growth trajectory, projected to reach $14,369.5 million by 2031, with an impressive Compound Annual Growth Rate (CAGR) of ...

Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...